{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024723","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.604621+00:00","generated_at":"2026-06-21T20:31:45.027013+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Crinetics Q3 net loss widens to $41.9M; paltusotine Phase 3 on track for Q3 2023 topline","bullets":["Net loss $41.9M in Q3 2022 vs $27.9M in Q3 2021; R&D spend rose to $32.0M from $21.6M.","Cash and investments $368.4M as of Sep 30, 2022, up from $333.7M at Dec 31, 2021.","Phase 3 PATHFNDR-1 for paltusotine in acromegaly fully enrolled; topline data expected Q3 2023.","Long-term extension data: paltusotine maintained IGF-1 comparable to injected SRLs for up to 103 weeks; 89% preferred paltusotine.","Appointed Dana Pizzuti, M.D. as chief development officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024723","json":"https://secwatch.observer/filing/0000950170-22-024723.json","markdown":"https://secwatch.observer/filing/0000950170-22-024723.md","text":"https://secwatch.observer/filing/0000950170-22-024723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022024723/0000950170-22-024723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022024723/crnx-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:31:45.027013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa4681137b0fc6cc995cd23f65693fad8b012e41","claim":"Crinetics Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $0.5 million, net income $41.9 million.","evidence_excerpt":"$3.0 million. • Net loss for the three months ended September 30, 2022, was $41.9 million, compared to a net loss of $27.9 million for the same period in 2021. • Revenues were $0.5 million for the three months ended September 30, 2022, consisting of license revenue recognized from the license agreement entered into with Sanwa Kagaku Kenkyusho Co., Ltd. in February","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022024723/0000950170-22-024723-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$0.5 million"},{"label":"Net income","value":"$41.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}